clinical trial · NCT07522073
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Solid TumorsINCB161734PlaceboInvestigator's choice of chemotherapy
brief summary
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
started
Apr 9, 2026
primary completion
Sep 15, 2028
completion
Mar 19, 2029
last updated
Jun 9, 2026
official title
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol